EUVIMEDEUVIMED entdecken
Crossref

Effect of Bevacizumab on Pterygium: A Case Series Study

Seyed Hashem Daryabari, Mahmood Hassani, Aliagha Alishiri

Journal of Ophthalmic and Optometric Sciences · 15.06.2025

DOI: 10.22037/joos.v8i4.48650 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ophthalmic and Optometric Sciences, erschienen am 15.06.2025. Verfasst von Seyed Hashem Daryabari und 2 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose: to study evaluate the effectiveness of a single subconjunctival injection of bevacizumab (Avastin), an anti-vascular endothelial growth factor (VEGF) agent, in reducing pterygium size and vascularization among patients with primary pterygium.Patients and Methods: Seventeen patients with primary pterygium were enrolled in this case series study. Each patient received a single subconjunctival injection of 1.25 mg bevacizumab. Follow-up evaluations were conducted at one week, one month, and three months post-injection. The primary outcomes included changes in symptoms such as itching, redness, tearing, and burning, as well as pterygium size and vascularization. Statistical analysis was performed using Repeated Measures ANOVA and Paired T-tests.

Results

Itching significantly decreased within the first week and remained stable at three months. Pterygium vascularization was also reduced. However, changes in pterygium size, astigmatism, and refraction were not statistically significant. No serious adverse effects were reported.

Conclusion

A single dose injection of subconjunctival bevacizumab significantly reduces vascularization and itching in pterygium. However, its impact on pterygium size remains unclear. While surgical excision remains the gold standard, subconjunctival bevacizumab offers an alternative treatment approach for patients seeking a minimally invasive alternative. Further studies are needed to determine optimal dosing strategies and long-term effects.

Schlagwörter

bevacizumabpterygiumsubconjunctival injectionanti-VEGF therapypterygium sizepruritusastigmatismminimally invasive treatment

Zitieren

APA

Daryabari, S. H., Hassani, M., & Alishiri, A. (2025). Effect of Bevacizumab on Pterygium: A Case Series Study. Journal of Ophthalmic and Optometric Sciences. https://doi.org/10.22037/joos.v8i4.48650

Vancouver

Daryabari SH, Hassani M, Alishiri A. Effect of Bevacizumab on Pterygium: A Case Series Study. Journal of Ophthalmic and Optometric Sciences. 2025. doi:10.22037/joos.v8i4.48650

BibTeX
@article{Daryabari2025,
  author = {Daryabari, Seyed Hashem and Hassani, Mahmood and Alishiri, Aliagha},
  title = {Effect of Bevacizumab on Pterygium: A Case Series Study},
  journal = {Journal of Ophthalmic and Optometric Sciences},
  year = {2025},
  doi = {10.22037/joos.v8i4.48650}
}
Kostenlos starten →